Margriet R Timmer1, Pierre Martinez2, Chiu T Lau1, Wytske M Westra1, Silvia Calpe1, Agnieszka M Rygiel1, Wilda D Rosmolen1, Sybren L Meijer3, Fiebo J W Ten Kate3, Marcel G W Dijkgraaf4, Rosalie C Mallant-Hent5, Anton H J Naber6, Arnoud H A M van Oijen7, Lubbertus C Baak8, Pieter Scholten9, Clarisse J M Böhmer10, Paul Fockens1, Carlo C Maley11, Trevor A Graham2, Jacques J G H M Bergman1, Kausilia K Krishnadath1. 1. Department of Gastroenterology and Hepatology, Academic Medical Centre-University of Amsterdam, Amsterdam, The Netherlands. 2. Evolution and Cancer Laboratory, Centre for Tumour Biology, Barts Cancer Institute, London, UK. 3. Department of Pathology, Academic Medical Centre-University of Amsterdam, Amsterdam, The Netherlands. 4. Clinical Research Unit, Academic Medical Centre-University of Amsterdam, Amsterdam, The Netherlands. 5. Department of Gastroenterology, Flevoziekenhuis, Almere, The Netherlands. 6. Department of Gastroenterology, Tergooiziekenhuizen, Hilversum, The Netherlands. 7. Department of Gastroenterology, Medisch Centrum Alkmaar, Alkmaar, The Netherlands. 8. Department of Gastroenterology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands. 9. Department of Gastroenterology, Sint Lucas Andreas Ziekenhuis, Amsterdam, The Netherlands. 10. Department of Gastroenterology, Spaarne Ziekenhuis, Hoofddorp, The Netherlands. 11. Centre for Evolution and Cancer, University of California at San Francisco, San Francisco, California, USA.
Abstract
OBJECTIVE: The risk of developing adenocarcinoma in non-dysplastic Barrett's oesophagus is low and difficult to predict. Accurate tools for risk stratification are needed to increase the efficiency of surveillance. We aimed to develop a prediction model for progression using clinical variables and genetic markers. METHODS: In a prospective cohort of patients with non-dysplastic Barrett's oesophagus, we evaluated six molecular markers: p16, p53, Her-2/neu, 20q, MYC and aneusomy by DNA fluorescence in situ hybridisation on brush cytology specimens. Primary study outcomes were the development of high-grade dysplasia or oesophageal adenocarcinoma. The most predictive clinical variables and markers were determined using Cox proportional-hazards models, receiver operating characteristic curves and a leave-one-out analysis. RESULTS: A total of 428 patients participated (345 men; median age 60 years) with a cumulative follow-up of 2019 patient-years (median 45 months per patient). Of these patients, 22 progressed; nine developed high-grade dysplasia and 13 oesophageal adenocarcinoma. The clinical variables, age and circumferential Barrett's length, and the markers, p16 loss, MYC gain and aneusomy, were significantly associated with progression on univariate analysis. We defined an 'Abnormal Marker Count' that counted abnormalities in p16, MYC and aneusomy, which significantly improved risk prediction beyond using just age and Barrett's length. In multivariate analysis, these three factors identified a high-risk group with an 8.7-fold (95% CI 2.6 to 29.8) increased HR when compared with the low-risk group, with an area under the curve of 0.76 (95% CI 0.66 to 0.86). CONCLUSIONS: A prediction model based on age, Barrett's length and the markers p16, MYC and aneusomy determines progression risk in non-dysplastic Barrett's oesophagus. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
OBJECTIVE: The risk of developing adenocarcinoma in non-dysplastic Barrett's oesophagus is low and difficult to predict. Accurate tools for risk stratification are needed to increase the efficiency of surveillance. We aimed to develop a prediction model for progression using clinical variables and genetic markers. METHODS: In a prospective cohort of patients with non-dysplastic Barrett's oesophagus, we evaluated six molecular markers: p16, p53, Her-2/neu, 20q, MYC and aneusomy by DNA fluorescence in situ hybridisation on brush cytology specimens. Primary study outcomes were the development of high-grade dysplasia or oesophageal adenocarcinoma. The most predictive clinical variables and markers were determined using Cox proportional-hazards models, receiver operating characteristic curves and a leave-one-out analysis. RESULTS: A total of 428 patients participated (345 men; median age 60 years) with a cumulative follow-up of 2019 patient-years (median 45 months per patient). Of these patients, 22 progressed; nine developed high-grade dysplasia and 13 oesophageal adenocarcinoma. The clinical variables, age and circumferential Barrett's length, and the markers, p16 loss, MYC gain and aneusomy, were significantly associated with progression on univariate analysis. We defined an 'Abnormal Marker Count' that counted abnormalities in p16, MYC and aneusomy, which significantly improved risk prediction beyond using just age and Barrett's length. In multivariate analysis, these three factors identified a high-risk group with an 8.7-fold (95% CI 2.6 to 29.8) increased HR when compared with the low-risk group, with an area under the curve of 0.76 (95% CI 0.66 to 0.86). CONCLUSIONS: A prediction model based on age, Barrett's length and the markers p16, MYC and aneusomy determines progression risk in non-dysplastic Barrett's oesophagus. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Entities:
Keywords:
BARRETT'S OESOPHAGUS; CANCER GENETICS; ENDOSCOPY; OESOPHAGEAL CANCER; SURVEILLANCE
Authors: Stuart J Spechler; Prateek Sharma; Rhonda F Souza; John M Inadomi; Nicholas J Shaheen Journal: Gastroenterology Date: 2011-03 Impact factor: 22.682
Authors: M Sikkema; C W N Looman; E W Steyerberg; M Kerkhof; F Kastelein; H van Dekken; A J van Vuuren; W A Bode; H van der Valk; R J T Ouwendijk; R Giard; W Lesterhuis; R Heinhuis; E C Klinkenberg; G A Meijer; F ter Borg; J W Arends; J J Kolkman; J van Baarlen; R A de Vries; A H Mulder; A J P van Tilburg; G J A Offerhaus; F J W ten Kate; J G Kusters; E J Kuipers; P D Siersema Journal: Am J Gastroenterol Date: 2011-05-17 Impact factor: 10.864
Authors: Carlo C Maley; Patricia C Galipeau; Jennifer C Finley; V Jon Wongsurawat; Xiaohong Li; Carissa A Sanchez; Thomas G Paulson; Patricia L Blount; Rosa-Ana Risques; Peter S Rabinovitch; Brian J Reid Journal: Nat Genet Date: 2006-03-26 Impact factor: 38.330
Authors: Louisa G Gordon; George C Mayne; Nicholas G Hirst; Timothy Bright; David C Whiteman; David I Watson Journal: Gastrointest Endosc Date: 2013-09-27 Impact factor: 9.427
Authors: Prateek Sharma; John Dent; David Armstrong; Jacques J G H M Bergman; Liebwin Gossner; Yoshio Hoshihara; Janusz A Jankowski; Ola Junghard; Lars Lundell; Guido N J Tytgat; Michael Vieth Journal: Gastroenterology Date: 2006-08-16 Impact factor: 22.682
Authors: Frederik Hvid-Jensen; Lars Pedersen; Asbjørn Mohr Drewes; Henrik Toft Sørensen; Peter Funch-Jensen Journal: N Engl J Med Date: 2011-10-13 Impact factor: 91.245
Authors: Emily G Barr Fritcher; Shannon M Brankley; Benjamin R Kipp; Jesse S Voss; Michael B Campion; Larry E Morrison; Mona S Legator; Lori S Lutzke; Kenneth K Wang; Thomas J Sebo; Kevin C Halling Journal: Hum Pathol Date: 2008-07-07 Impact factor: 3.466
Authors: Patricia C Galipeau; Xiaohong Li; Patricia L Blount; Carlo C Maley; Carissa A Sanchez; Robert D Odze; Kamran Ayub; Peter S Rabinovitch; Thomas L Vaughan; Brian J Reid Journal: PLoS Med Date: 2007-02 Impact factor: 11.069
Authors: Rebecca C Fitzgerald; Massimiliano di Pietro; Krish Ragunath; Yeng Ang; Jin-Yong Kang; Peter Watson; Nigel Trudgill; Praful Patel; Philip V Kaye; Scott Sanders; Maria O'Donovan; Elizabeth Bird-Lieberman; Pradeep Bhandari; Janusz A Jankowski; Stephen Attwood; Simon L Parsons; Duncan Loft; Jesper Lagergren; Paul Moayyedi; Georgios Lyratzopoulos; John de Caestecker Journal: Gut Date: 2013-10-28 Impact factor: 23.059
Authors: James P Moriarty; Nilay D Shah; Joel H Rubenstein; Christopher H Blevins; Michele Johnson; David A Katzka; Kenneth K Wang; Louis Michel Wongkeesong; David A Ahlquist; Prasad G Iyer Journal: Gastrointest Endosc Date: 2017-04-25 Impact factor: 9.427
Authors: J Nwachokor; O Tawfik; M Danley; S Mathur; J House; P Sharma; L K Christenson; A Bansal Journal: Dis Esophagus Date: 2017-09-01 Impact factor: 3.429
Authors: Matthew D Stachler; Nicholas D Camarda; Christopher Deitrick; Anthony Kim; Agoston T Agoston; Robert D Odze; Jason L Hornick; Anwesha Nag; Aaron R Thorner; Matthew Ducar; Amy Noffsinger; Richard H Lash; Mark Redston; Scott L Carter; Jon M Davison; Adam J Bass Journal: Gastroenterology Date: 2018-03-31 Impact factor: 22.682
Authors: Christopher Douville; Helen R Moinova; Prashanthi N Thota; Nicholas J Shaheen; Prasad G Iyer; Marcia Irene Canto; Jean S Wang; John A Dumot; Ashley Faulx; Kenneth W Kinzler; Nickolas Papadopoulos; Bert Vogelstein; Sanford D Markowitz; Chetan Bettegowda; Joseph E Willis; Amitabh Chak Journal: Gastroenterology Date: 2021-01-22 Impact factor: 22.682